# TG Therapeutics, Inc.: overview

TGTX · Nasdaq · CIK 1001316 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tgtx.md) · [Financials](/companies/tgtx/financials.md) · [Filings](/companies/tgtx/filings.md) · [Insiders](/companies/tgtx/insiders.md)

Latest reported revenue: [$240.3m](/filings/0001437749-26-025955.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-025955).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [83.9](/filings/0001437749-25-033363.md) | [108 d](/filings/0001437749-26-006133.md) | [121](/filings/0001437749-26-015246.md) | [141](/filings/0001437749-26-025955.md) | [162](/filings/0001437749-25-033363.md) | [193 d](/filings/0001437749-26-006133.md) | [205](/filings/0001437749-26-015246.md) | [240](/filings/0001437749-26-025955.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [14.8%](/filings/0001437749-25-033363.md) | [27.7% d](/filings/0001437749-26-006133.md) | [7.1%](/filings/0001437749-26-015246.md) | [24.7%](/filings/0001437749-26-025955.md) | [18.2%](/filings/0001437749-25-033363.md) | [26.2% d](/filings/0001437749-26-006133.md) | [17.0%](/filings/0001437749-26-015246.md) | [9.0%](/filings/0001437749-26-025955.md) |
| Net margin | % | [4.6%](/filings/0001437749-25-033363.md) | [21.6% d](/filings/0001437749-26-006133.md) | [4.2%](/filings/0001437749-26-025955.md) | [20.0%](/filings/0001437749-26-025955.md) | [241.7%](/filings/0001437749-25-033363.md) | [12.0% d](/filings/0001437749-26-006133.md) | [9.7%](/filings/0001437749-26-025955.md) | [3.2%](/filings/0001437749-26-025955.md) |
| Diluted EPS | $ per share | [0.02](/filings/0001437749-25-033363.md) | not reported | [0.03](/filings/0001437749-26-015246.md) | [0.17](/filings/0001437749-26-025955.md) | [2.43](/filings/0001437749-25-033363.md) | not reported | [0.12](/filings/0001437749-26-015246.md) | [0.05](/filings/0001437749-26-025955.md) |
| Free cash flow | $m | [(12.2) d](/filings/0001437749-25-033363.md) | [(25.7) d](/filings/0001437749-26-006133.md) | [(28.7)](/filings/0001437749-26-015246.md) | [7.4 d](/filings/0001437749-26-025955.md) | [(23.2) d](/filings/0001437749-25-033363.md) | [19.6 d](/filings/0001437749-26-006133.md) | [(17.9)](/filings/0001437749-26-015246.md) | [39.0 d](/filings/0001437749-26-025955.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.7](/filings/0001437749-24-006144.md) | [2.8](/filings/0001437749-25-005908.md) | [234](/filings/0001437749-26-006133.md) | [329](/filings/0001437749-26-006133.md) | [616](/filings/0001437749-26-006133.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(5154.3%)](/filings/0001437749-24-006144.md) | [(7839.0%)](/filings/0001437749-25-005908.md) | [8.8%](/filings/0001437749-26-006133.md) | [12.7%](/filings/0001437749-26-006133.md) | [20.0%](/filings/0001437749-26-006133.md) |
| Net margin | % | [(5204.1%)](/filings/0001437749-24-006144.md) | [(8036.3%)](/filings/0001437749-25-005908.md) | [5.4%](/filings/0001437749-26-006133.md) | [7.1%](/filings/0001437749-26-006133.md) | [72.6%](/filings/0001437749-26-006133.md) |
| Diluted EPS | $ per share | [(2.63)](/filings/0001437749-24-006144.md) | [(1.65)](/filings/0001437749-25-005908.md) | [0.09](/filings/0001437749-26-006133.md) | [0.15](/filings/0001437749-26-006133.md) | [2.77](/filings/0001437749-26-006133.md) |
| Free cash flow | $m | [(296)](/filings/0001437749-24-006144.md) | [(176)](/filings/0001437749-25-005908.md) | [(31.4)](/filings/0001437749-26-006133.md) | [(40.6)](/filings/0001437749-26-006133.md) | [(25.0)](/filings/0001437749-26-006133.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tgtx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.21bn | 22,050,045 |  | Reduced −202,885 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $437.5m | 7,963,266 |  | Reduced −310,713 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $427.8m | 7,786,471 |  | Reduced −863,295 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $337.8m | 6,149,403 |  | Reduced −453,855 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $200.1m | 3,642,216 |  | Added +142,300 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $186.8m | 3,400,808 |  | Added +2,810,761 |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $160.9m | 2,927,895 |  | Reduced −1,101,424 |
| [Clearbridge Investments, LLC](/funds/1348883.md) | 2026-06-30 | $145.6m | 2,650,192 |  | Reduced −560,738 |
| [CONGRESS ASSET MANAGEMENT CO](/funds/897378.md) | 2026-06-30 | $142.9m | 2,600,123 |  | Added +432,042 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $135.6m | 2,468,971 |  | Added +926,659 |

## Recent filings

[All 700 filings](/companies/tgtx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 17:01 ET | [10-Q](/filings/0001437749-26-025955.md) | Quarterly report, period 2026-06-30 | 0001437749-26-025955 |
| 2026-08-03 | 07:05 ET | [8-K](/filings/0001437749-26-025304.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-025304 |
| 2026-06-12 | 16:32 ET | [8-K](/filings/0001437749-26-020491.md) | 5.07 Shareholder vote results | 0001437749-26-020491 |
| 2026-06-03 | 07:34 ET | [8-K](/filings/0001437749-26-019262.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-019262 |
| 2026-05-27 | 16:34 ET | [8-K](/filings/0001437749-26-018586.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-018586 |
| 2026-05-06 | 17:00 ET | [10-Q](/filings/0001437749-26-015246.md) | Quarterly report, period 2026-03-31 | 0001437749-26-015246 |
| 2026-05-06 | 07:25 ET | [8-K](/filings/0001437749-26-015013.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-015013 |
| 2026-04-30 | 16:31 ET | [DEF 14A](/filings/0001437749-26-014233.md) | Proxy statement, period 2026-06-11 | 0001437749-26-014233 |
| 2026-03-20 | 16:33 ET | [8-K](/filings/0001437749-26-009253.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001437749-26-009253 |
| 2026-02-27 | 17:05 ET | [10-K](/filings/0001437749-26-006133.md) | Annual report, period 2025-12-31 | 0001437749-26-006133 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-006133.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/062db211-a984-467f-a605-d24f334ec85b)

## About the filer

- CIK: 1001316
- Tickers: TGTX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.